Form 8-K - Current report:
SEC Accession No. 0001493152-25-001069
Filing Date
2025-01-06
Accepted
2025-01-06 17:23:09
Documents
16
Period of Report
2025-01-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 46899
2 ex5-1.htm EX-5.1 13617
3 ex10-1.htm EX-10.1 285449
  Complete submission text file 0001493152-25-001069.txt   628740

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE lixt-20250106.xsd EX-101.SCH 3519
5 XBRL DEFINITION FILE lixt-20250106_def.xml EX-101.DEF 29971
6 XBRL LABEL FILE lixt-20250106_lab.xml EX-101.LAB 36548
7 XBRL PRESENTATION FILE lixt-20250106_pre.xml EX-101.PRE 26994
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5396
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 25512394
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)